Memorializing Governor Kathy Hochul to proclaim June 10, 2025, as FSGS Awareness Day in the State of New York
This resolution memorializes Governor Kathy Hochul to proclaim June 10, 2025, as FSGS Awareness Day in New York State. It is a commemorative measure focused on raising public awareness of focal segmental glomerulosclerosis (FSGS), a rare kidney disease that causes scarring in the kidneys and can progress to kidney failure, dialysis, or transplant. The resolution describes the disease burden, the difficulty of diagnosis, and the need for earlier detection, better access to specialized care, and continued research into treatments.
The resolution also highlights the broader public health and economic impact of FSGS, including its effects on Medicaid, Medicare, private insurance, and communities disproportionately affected by kidney disease. It emphasizes that FSGS can affect adults of any age but is especially common in adults over 45, and that it disproportionately impacts African Americans, in part due to APOL1 gene variants. The measure is largely symbolic and does not create a new program, benefit, or regulatory requirement; instead, it urges state recognition of the awareness day and transmits copies to the Governor and NephCure.
The bill does not amend the Public Health Law, Insurance Law, Medicaid rules, or any other statute. Its legal effect is limited to a legislative memorialization asking the Governor to issue a proclamation designating June 10, 2025, as FSGS Awareness Day. The practical impact is public-facing: it may help elevate awareness, encourage screening and diagnosis, support patients and families, and draw attention to research and treatment development for rare kidney disease.
The overall sentiment reflected in the resolution is strongly supportive and sympathetic toward patients, families, clinicians, researchers, and advocacy organizations working on FSGS. The bill presents the disease as serious, costly, and underrecognized, and it frames the awareness day as a positive step toward education, early detection, and future therapies. No committee debate or recorded votes are provided, so there is no evidence of opposition in the available materials.
There is no recorded controversy, committee testimony, or vote history in the provided context, so no specific points of contention are documented. If any concerns were to arise, they would likely relate to the resolution’s emphasis on health disparities, the cost burden on public and private insurance systems, or the use of state recognition for a disease-specific awareness observance, but none of these issues are shown as disputed in the available record.